Gene Solutions Genomics Malaysia participated in the Annual Scientific Meeting of Malaysian Society of Gastroenterology & Hepatology (MSGH), GUT 2024 conference held at Sabah International Convention Centre, Kota Kinabalu over the weekend, by primarily showcasing its latest technology in multi-cancer early detection (MCED), and the SPOT-MAS test.
SPOT-MAS detects and analyzes the presence of circulating tumour DNA (ctDNA) and methylation profiles of the 5 most common cancers today (breast, liver, lung, colon, stomach), via a simple blood draw and next-generation sequencing (NGS) with high sensitivity and specificity. As a first stage cancer screening test, SPOT-MAS complements existing cancer screening methods for a combined effective screening strategy.
Datuk Dr Raman Muthukaruppan, the Organising Chair of GUT 2024, also the President of MSGH, accompanied by Dr Sattian Kollanthavelu, the Honorary Treasurer of MSGH, visited our booth where we got to share the latest advancement on cancer screening via liquid biopsy technology. This is also acknowledged by experts attending GUT 2024, namely internal medicine specialists, gastroenterologists and hepatologists, and surgeons from the private and public sectors.
Our team is delighted to have received the well-known Sabahan warm hospitality and the opportunity to raise awareness of MCED among the attendees of the conference.
About Gene Solutions Malaysia
Gene Solutions established its operations and services in Malaysia in 2023 and is committed to provide the local community access to next-generation genetic tests that support reproductive health and clinical oncology. In the field of clinical oncology, personalized minimal residual disease (MRD) detection, and multi-cancer early detection (MCED) tests using advanced ctDNA technology are among some of the products available. Partnering with local laboratory partners Premier Integrated Lab and Innoquest Malaysia, Gene Solutions Malaysia is committed to enhancing healthcare with their innovative genetic solutions.
